Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure.

[1]  M. Etminan,et al.  Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. , 2006, Journal of the American College of Cardiology.

[2]  S. Bandinelli,et al.  Relation of angiotensin-converting enzyme inhibitor treatment to insulin-like growth factor-1 serum levels in subjects >65 years of age (the InCHIANTI study). , 2006, The American journal of cardiology.

[3]  M. Meysman.  Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial , 2006, European Respiratory Journal.

[4]  J. Penninger,et al.  Angiotensin-converting enzyme 2 in lung diseases , 2006, Current Opinion in Pharmacology.

[5]  A. Tajik,et al.  Diastolic heart failure can be diagnosed by comprehensive two-dimensional and Doppler echocardiography. , 2006, Journal of the American College of Cardiology.

[6]  C. Schindler,et al.  Use of B-type natriuretic peptide in the management of acute dyspnea in patients with pulmonary disease. , 2006, American heart journal.

[7]  J. H. Patterson,et al.  Executive Summary Executive Summary : HFSA 2010 Comprehensive Heart Failure Practice Guideline , 2022 .

[8]  A. Rigby,et al.  Effect of a community heart failure clinic on uptake of β blockers by patients with obstructive airways disease and heart failure , 2005, Heart.

[9]  Judith K Jones,et al.  Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. , 2006, Annals of epidemiology.

[10]  Mitchell J. Barnett,et al.  β‐Blocker Therapy in Veterans with Asthma or Chronic Obstructive Pulmonary Disease , 2005 .

[11]  M. Son,et al.  Pharmacokinetics and Biodistribution of a pGT2-VEGF Plasmid DNA After Administration in Rats , 2005, Journal of cardiovascular pharmacology.

[12]  T. Shim,et al.  Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. , 2005, American journal of respiratory and critical care medicine.

[13]  Fernando Holguin,et al.  Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. , 2005, Chest.

[14]  S. Sidney,et al.  COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. , 2005, Chest.

[15]  A. Cohen-Solal,et al.  Dissociation Between Improvement in Left Ventricular Performance and Functional Class in Patients With Chronic Heart Failure , 2005, Journal of cardiovascular pharmacology.

[16]  K. Kangawa,et al.  Treatment of cachexia with ghrelin in patients with COPD. , 2005, Chest.

[17]  N. Morrell,et al.  Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease , 2005, Respiratory research.

[18]  M. Egred,et al.  Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. , 2005, QJM : monthly journal of the Association of Physicians.

[19]  J. Hollander,et al.  B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea. , 2005, Chest.

[20]  G. Mancini.  The 'double dip' hypothesis: simultaneous prevention of cardiovascular and pulmonary morbidity and mortality using angiotensin II type 1 receptor blockers. , 2005, The Canadian journal of cardiology.

[21]  V. Hasselblad,et al.  Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. , 2005, Journal of cardiac failure.

[22]  K. Kangawa,et al.  Ghrelin: structure and function. , 2005, Physiological reviews.

[23]  D. Postma,et al.  Clinical Investigations: COPDDetrimental Effects of β-Blockers in COPD: A Concern for Nonselective β-Blockers , 2005 .

[24]  Ulf Dahlström,et al.  Frequent non‐cardiac comorbidities in patients with chronic heart failure , 2005, European journal of heart failure.

[25]  Jillian G. Baker,et al.  The selectivity of β‐adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors , 2005 .

[26]  Hsin C. Lin,et al.  Insulin-like Growth Factor-1 (IGF-1) Inversely Regulates Atrophy-induced Genes via the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin (PI3K/Akt/mTOR) Pathway* , 2005, Journal of Biological Chemistry.

[27]  E. Salpeter,et al.  Cardioselective beta-blockers for chronic obstructive pulmonary disease. , 2005, The Cochrane database of systematic reviews.

[28]  J. Baker.  The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. , 2005, British journal of pharmacology.

[29]  D. Postma,et al.  Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. , 2005, Chest.

[30]  F. Rutten,et al.  Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. , 2005, European heart journal.

[31]  P. Kaboli,et al.  beta-Blocker therapy in veterans with asthma or chronic obstructive pulmonary disease. , 2005, Pharmacotherapy.

[32]  WataruShimizu,et al.  Effects of Ghrelin Administration on Left Ventricular Function, Exercise Capacity, and Muscle Wasting in Patients With Chronic Heart Failure , 2004 .

[33]  S. Kandarian,et al.  The molecular basis of skeletal muscle atrophy. , 2004, American journal of physiology. Cell physiology.

[34]  A. Goldberg,et al.  IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. , 2004, American journal of physiology. Endocrinology and metabolism.

[35]  J. Hollander,et al.  Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. , 2004, Journal of the American College of Cardiology.

[36]  L. D. Libera,et al.  Muscle wastage in chronic heart failure, between apoptosis, catabolism and altered anabolism: a chimaeric view of inflammation? , 2004, Current opinion in clinical nutrition and metabolic care.

[37]  D. Guttridge.  Signaling pathways weigh in on decisions to make or break skeletal muscle , 2004, Current opinion in clinical nutrition and metabolic care.

[38]  A Senthilselvan,et al.  Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis , 2004, Thorax.

[39]  E. Salpeter,et al.  Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. , 2004, Chest.

[40]  J. McMurray,et al.  Poor concordance of commonly used echocardiographic measures of left ventricular diastolic function in patients with suspected heart failure but preserved systolic function: is there a reliable echocardiographic measure of diastolic dysfunction? , 2004, Heart.

[41]  Marco Sandri,et al.  Foxo Transcription Factors Induce the Atrophy-Related Ubiquitin Ligase Atrogin-1 and Cause Skeletal Muscle Atrophy , 2004, Cell.

[42]  P. Callaerts,et al.  Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. McMurray,et al.  Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) , 2004, Circulation.

[44]  D. Sin,et al.  Are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular morbidity and mortality , 2004 .

[45]  P. Callaerts,et al.  Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[46]  W. Mitch,et al.  Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. , 2004, The Journal of clinical investigation.

[47]  P. Dorow,et al.  Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris , 2004, European Journal of Clinical Pharmacology.

[48]  L. Køber,et al.  Female sex is associated with a better long-term survival in patients hospitalized with congestive heart failure. , 2004, European heart journal.

[49]  F. van Lente,et al.  Plasma B-Type Natriuretic Peptide Levels in Ambulatory Patients With Established Chronic Symptomatic Systolic Heart Failure , 2003, Circulation.

[50]  Albert W Wu,et al.  Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. , 2003, Journal of the American College of Cardiology.

[51]  G. Berry,et al.  Simvastatin Rescues Rats From Fatal Pulmonary Hypertension by Inducing Apoptosis of Neointimal Smooth Muscle Cells , 2003, Circulation.

[52]  A. Çamsarı,et al.  Metoprolol, a Β-1 selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease , 2003, Heart and Vessels.

[53]  I. Hall,et al.  Influence of agonist efficacy and receptor phosphorylation on antagonist affinity measurements: differences between second messenger and reporter gene responses. , 2003, Molecular pharmacology.

[54]  M. Hori,et al.  Short-Term Statin Therapy Improves Cardiac Function and Symptoms in Patients With Idiopathic Dilated Cardiomyopathy , 2003, Circulation.

[55]  E. Chung,et al.  Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial , 2003, Circulation.

[56]  Alun Jones,et al.  Skeletal muscle RAS and exercise performance. , 2003, The international journal of biochemistry & cell biology.

[57]  J. Curtis,et al.  Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. , 2003, Chest.

[58]  D. Matthews,et al.  Effect of heart failure on the regulation of skeletal muscle protein synthesis, breakdown, and apoptosis. , 2003, American journal of physiology. Endocrinology and metabolism.

[59]  E. Wouters,et al.  Striking similarities in systemic factors contributing to decreased exercise capacity in patients with severe chronic heart failure or COPD. , 2003, Chest.

[60]  Abdissa Negassa,et al.  Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study , 2003, The Lancet.

[61]  D. Sin,et al.  Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. , 2003, Circulation.

[62]  D. Glass.  Signalling pathways that mediate skeletal muscle hypertrophy and atrophy , 2003, Nature Cell Biology.

[63]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.

[64]  A. Çamsarı,et al.  Metoprolol, a beta-1 selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease. , 2003, Heart and vessels.

[65]  P. Macdonald,et al.  Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[66]  N. Chavannes,et al.  Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. , 2002, American journal of respiratory and critical care medicine.

[67]  R. Wurdeman,et al.  ACE Inhibitor—Induced Bronchial Reactivity in Patients with Respiratory Dysfunction , 2002, The Annals of pharmacotherapy.

[68]  G. Schuler,et al.  Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure. , 2002, Journal of the American College of Cardiology.

[69]  H. Krumholz,et al.  Spectrum of heart failure in older patients: results from the National Heart Failure project. , 2002, American heart journal.

[70]  D. Postma,et al.  Chronic obstructive pulmonary disease. , 2002, Clinical evidence.

[71]  S. Liggett,et al.  Targeted transgenic expression of beta(2)-adrenergic receptors to type II cells increases alveolar fluid clearance. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[72]  M. Cicoira,et al.  Skeletal muscle mass independently predicts peak oxygen consumption and ventilatory response during exercise in noncachectic patients with chronic heart failure. , 2001, Journal of the American College of Cardiology.

[73]  H. Krumholz,et al.  Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. , 2001, Journal of the American College of Cardiology.

[74]  D. Chemla,et al.  Angiotensin-converting enzyme inhibitor therapy improves respiratory muscle strength in patients with heart failure. , 2001, Chest.

[75]  E. Bozkanat,et al.  Skeletal muscle dysfunction in chronic obstructive pulmonary disease , 2001, Respiratory research.

[76]  A. Goldberg,et al.  What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? , 2001, Current opinion in clinical nutrition and metabolic care.

[77]  L. Badano,et al.  Specialty-related differences in the epidemiology, clinical profile, management and outcome of patients hospitalized for heart failure; the OSCUR study. Oucome dello Scompenso Cardiaco in relazione all'Utilizzo delle Risore. , 2001, European heart journal.

[78]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[79]  R. Casaburi.  Skeletal muscle dysfunction in chronic obstructive pulmonary disease. , 1999, Medicine and science in sports and exercise.

[80]  Christine Jenkins,et al.  GOLD SCIENTIFIC COMMITTEE. GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. NHLBI/WHO GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE (COLD) WORKSHOP SUMMARY , 2001 .

[81]  T. Yoneda,et al.  Distribution of muscle mass and maximal exercise performance in patients with COPD. , 2001, Chest.

[82]  P. Macdonald,et al.  Baseline predictors of tolerability to carvedilol in patients with chronic heart failure , 2000, Heart.

[83]  Dirkje S Postma,et al.  Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study , 2000, The Lancet.

[84]  M. Decramer,et al.  Skeletal muscle dysfunction in chronic obstructive pulmonary disease and chronic heart failure: underlying mechanisms and therapy perspectives. , 2000, The American journal of clinical nutrition.

[85]  J. Barberà,et al.  Effects of Endurance Training on Skeletal Muscle Bioenergetics in Chronic Obstructive Pulmonary Disease , 1999 .

[86]  P. Macdonald,et al.  Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. , 1999, Journal of the American College of Cardiology.

[87]  F. Maltais,et al.  Histochemical and morphological characteristics of the vastus lateralis muscle in patients with chronic obstructive pulmonary disease. , 1998, Medicine and science in sports and exercise.

[88]  S. Gottlieb,et al.  Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. , 1998, The New England journal of medicine.

[89]  M. Cazzola,et al.  Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. , 1998, Chest.

[90]  P. Poole‐Wilson,et al.  Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. , 1998, Journal of the American College of Cardiology.

[91]  N. Dunn,et al.  Risk of non-fatal cardiac failure and ischaemic heart disease with long acting β2 agonists , 1998, Thorax.

[92]  R. Hershberger,et al.  Managed care and outcomes of hospitalization among elderly patients with congestive heart failure. , 1998, Archives of internal medicine.

[93]  D. Chatel,et al.  Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. , 1998, Circulation.

[94]  P. Ponikowski,et al.  Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. , 1997, Journal of the American College of Cardiology.

[95]  A. Goldberg,et al.  Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. , 1996, The New England journal of medicine.

[96]  T. LeJemtel,et al.  Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. , 1996, Journal of the American College of Cardiology.

[97]  J R Florini,et al.  Growth hormone and the insulin-like growth factor system in myogenesis. , 1996, Endocrine reviews.

[98]  V M Hawthorne,et al.  Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study , 1996, BMJ.

[99]  B. Lipworth,et al.  Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. , 1996, Thorax.

[100]  M. Render,et al.  Left ventricular dysfunction in deteriorating patients with chronic obstructive pulmonary disease. , 1995, Chest.

[101]  T. LeJemtel,et al.  Active Skeletal Muscle Mass and Cardiopulmonary Reserve: Failure to Attain Peak Aerobic Capacity During Maximal Bicycle Exercise in Patients With Severe Congestive Heart Failure , 1992, Circulation.

[102]  N. Jones,et al.  Exercise capacity and ventilatory, circulatory, and symptom limitation in patients with chronic airflow limitation. , 1992, The American review of respiratory disease.

[103]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[104]  M. Higginbotham,et al.  Exercise training in patients with severe left ventricular dysfunction. Hemodynamic and metabolic effects. , 1988, Circulation.

[105]  A. Wellstein,et al.  Reduction of exercise tachycardia in man after propranolol, atenolol and bisoprolol in comparison to beta-adrenoceptor occupancy. , 1987, European heart journal.

[106]  P. Barnes,et al.  Autoradiographic visualization of beta-adrenoceptor subtypes in human lung. , 1985, The American review of respiratory disease.

[107]  J. Lammers,et al.  Ventilatory effects of long-term treatment with pindolol and metoprolol in hypertensive patients with chronic obstructive lung disease. , 1985, British journal of clinical pharmacology.

[108]  R. Fitts.  Alterations in skeletal muscle with disuse atrophy , 1984 .

[109]  P. Fenster,et al.  Effect of metoprolol on cardiac and pulmonary function in chronic obstructive pulmonary disease , 1983, Clinical cardiology.

[110]  S. Conrad,et al.  Effects of labetalol in hypertensive patients with chronic obstructive pulmonary disease. , 1983, Chest.

[111]  D. H. Jackson,et al.  Inhalation challenge with carbachol and isoproterenol to predict bronchospastic response to propranolol in COPD. , 1983, Chest.

[112]  H. Macha,et al.  Beta-adrenoceptor blockers and terbutaline in patients with chronic obstructive lung disease. Effects and interaction after oral administration. , 1980, Chest.

[113]  L. Tivenius.  Effects of muliple doses of metoprolol and propranolol on ventilatory function in patients with chronic obstructive lung disease. , 1976, Scandinavian journal of respiratory diseases.

[114]  J. Ellis,et al.  Left ventricular ejection fraction in severe chronic obstructive airways disease. , 1975, The American journal of medicine.

[115]  H. Kowarzyk.  Structure and Function. , 1910, Nature.